MRNS240517P8000
- 6.60
- 0.000.00%
Marinus Pharmaceuticals Newsroom
Sector Update: Health Care
Health care stocks were mixed late Friday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) adding 0.1%. The iShares Biotechnology ETF (IB
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent
Marinus Pharmaceuticals (MRNS) said Friday that it has completed enrollment in a phase 3 trial of oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex in children a
Here's Why Marinus Pharmaceuticals (MRNS) Is Poised for a Turnaround After Losing -7.8% in 4 Weeks
Buy Rating Affirmed: Marinus Pharmaceuticals' Advancements and Long-term Patent Protection Signal Strong Prospects
Marinus Pharmaceuticals Wraps Phase 3 Trial Enrollment for Tuberous Sclerosis Complex Treatment, Targets New Drug Application in 2025 Following Phase 3 Seizure Treatment Trial
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in th
Express News | Marinus Pharmaceuticals Inc: Enrollment Complete in Phase 3 Trusttsc Trial With Topline Data Anticipated in First Half of Q4 2024
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$6.67 Price Target
As you might know, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) last week released its latest first-quarter, and things did not turn out so great for shareholders. The numbers were weak, with reve
Buy Rating Affirmed for Marinus Pharmaceuticals Amidst Operational Progress and Strategic Cost Management
Express News | HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $11 Price Target
Marinus Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 648.3% HC Wainwright & Co. → $11 Reiterates Buy → Buy 05/07/2024 648.3% HC Wainwright & Co. $27
Express News | Marinus Pharmaceuticals Inc : Jefferies Cuts Target Price to $5 From $6
Marinus Stock Falls 9% Amid Q1 Report, Cost-cutting Measures
Buy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug Trials
Marinus Pharmaceuticals | 10-Q: Quarterly report
Marinus Pharmaceuticals Expects That Cash, Cash Equivalents And Short-term Investments Of $113.3M As Of March 31, 2024, Inclusive Of Cost Reduction Plans, Is Expected To Provide Cash Runway Into Q1 Of 2025
Marinus Pharmaceuticals Expects That Cash, Cash Equivalents And Short-term Investments Of $113.3M As Of March 31, 2024, Inclusive Of Cost Reduction Plans, Is Expected To Provide Cash Runway Into Q1 Of
Marinus Pharmaceuticals Has Increased 2024 Projected US ZTALMY Product Revenues To $33M-$35M From $32M-$34M
Marinus Pharmaceuticals Has Increased 2024 Projected US ZTALMY Product Revenues To $33M-$35M From $32M-$34M
Express News | Marinus Pharmaceuticals Inc -Increased Full Year 2024 Projected U.S. Ztalmy Net Product Revenues to Between $33 and $35 Mln
Express News | Marinus Pharmaceuticals Inc -Reduced the Company's Workforce by Approximately 20%
Express News | Marinus Pharmaceuticals Inc -Cash, Cash Equivalents and Short-Term Investments of $113.3 Mln as of March 31, 2024